|
2014-09-03 |
2014-09-02 |
VP
Vente planifiée
|
Powell Andrew Kenneth William
EVP, GC & Secretary
Dirigeant
|
7 500
-19.5%
73,47
551 035 USD
|
7 500
-19.5%
|
73,47
|
551 035 USD
|
|
|
2014-08-20 |
2014-08-15 |
VP
Vente planifiée
|
Di Nepi Giacomo
EVP Managing Director, Europe
Dirigeant
|
10 000
-25.9%
51,28
512 752 USD
|
10 000
-25.9%
|
51,28
|
512 752 USD
|
|
|
2014-08-14 |
2014-08-13 |
VP
Vente planifiée
|
ARATA PAUL D
EVP, Human Resources & Admin
Dirigeant
|
7 500
-25.5%
50,00
375 000 USD
|
7 500
-25.5%
|
50,00
|
375 000 USD
|
|
|
2014-08-14 |
2014-08-13 |
VP
Vente planifiée
|
Nolan Sean P.
EVP & CBO
Dirigeant
|
17 000
-20.6%
50,00
850 000 USD
|
17 000
-20.6%
|
50,00
|
850 000 USD
|
|
|
2014-08-07 |
2014-08-07 |
VP
Vente planifiée
|
WELCH DANIEL G
Chairman, CEO and President
Administrateur exécutif
|
24 900
-20.9%
45,17
1 124 813 USD
|
24 900
-20.9%
|
45,17
|
1 124 813 USD
|
|
|
2014-08-07 |
2014-08-05 |
VP
Vente planifiée
|
WELCH DANIEL G
Chairman, CEO and President
Administrateur exécutif
|
146 125
-60.8%
44,95
6 568 684 USD
|
146 125
-60.8%
|
44,95
|
6 568 684 USD
|
|
|
2014-07-17 |
2014-07-15 |
VP
Vente planifiée
|
Leff Jonathan A
EVP, Research & Development
Dirigeant
|
35 000
-43.1%
43,08
1 507 709 USD
|
35 000
-43.1%
|
43,08
|
1 507 709 USD
|
|
|
2014-06-20 |
2014-06-18 |
VP
Vente planifiée
|
Nolan Sean P.
EVP & CBO
Dirigeant
|
10 000
-13.2%
47,10
471 000 USD
|
10 000
-13.2%
|
47,10
|
471 000 USD
|
|
|
2014-06-18 |
2014-06-16 |
VP
Vente planifiée
|
WELCH DANIEL G
Chairman, CEO and President
Administrateur exécutif
|
15 000
-13.7%
45,02
675 252 USD
|
15 000
-13.7%
|
45,02
|
675 252 USD
|
|
|
2014-06-13 |
2014-06-13 |
VP
Vente planifiée
|
Nolan Sean P.
EVP & CBO
Dirigeant
|
10 000
-13.2%
44,35
443 500 USD
|
10 000
-13.2%
|
44,35
|
443 500 USD
|
|
|
2014-06-13 |
2014-06-06 |
VP
Vente planifiée
|
Nolan Sean P.
EVP & CBO
Dirigeant
|
10 000
-13.2%
41,25
412 500 USD
|
10 000
-13.2%
|
41,25
|
412 500 USD
|
|
|
2014-08-20 |
2014-06-04 |
V
Vente
|
Di Nepi Giacomo
EVP Managing Director, Europe
Dirigeant
|
12 085
-29.7%
39,79
480 902 USD
|
12 085
-29.7%
|
39,79
|
480 902 USD
|
|
|
2014-06-03 |
2014-05-30 |
V
Vente
|
Powell Andrew Kenneth William
EVP, GC & Secretary
Dirigeant
|
500
-1.6%
39,32
19 662 USD
|
500
-1.6%
|
39,32
|
19 662 USD
|
|
|
2014-06-03 |
2014-05-29 |
V
Vente
|
Powell Andrew Kenneth William
EVP, GC & Secretary
Dirigeant
|
500
-1.6%
39,56
19 780 USD
|
500
-1.6%
|
39,56
|
19 780 USD
|
|
|
2014-06-02 |
2014-05-29 |
V
Vente
|
KABAKOFF DAVID S
Administrateur non-exécutif
|
5 000
-18.8%
39,56
197 800 USD
|
5 000
-18.8%
|
39,56
|
197 800 USD
|
|
|
2014-05-28 |
2014-05-27 |
VP
Vente planifiée
|
WELCH DANIEL G
Chairman, CEO and President
Administrateur exécutif
|
6 949
-6.9%
40,15
278 970 USD
|
6 949
-6.9%
|
40,15
|
278 970 USD
|
|
|
2014-06-04 |
2014-05-23 |
VP
Vente planifiée
|
ARATA PAUL D
EVP, Human Resources & Admin
Dirigeant
|
10 000
-30.5%
40,00
400 000 USD
|
10 000
-30.5%
|
40,00
|
400 000 USD
|
|
|
2014-05-28 |
2014-05-23 |
VP
Vente planifiée
|
WELCH DANIEL G
Chairman, CEO and President
Administrateur exécutif
|
34 544
-26.9%
40,01
1 381 974 USD
|
34 544
-26.9%
|
40,01
|
1 381 974 USD
|
|
|
2014-05-21 |
2014-05-19 |
VP
Vente planifiée
|
WELCH DANIEL G
Charman, CEO and President
Administrateur exécutif
|
11 607
-11.0%
38,00
441 066 USD
|
11 607
-11.0%
|
38,00
|
441 066 USD
|
|
|
2014-05-07 |
2014-05-06 |
VP
Vente planifiée
|
WELCH DANIEL G
Chairman, CEO and President
Administrateur exécutif
|
31 519
-24.3%
36,01
1 135 012 USD
|
31 519
-24.3%
|
36,01
|
1 135 012 USD
|
|
|
2014-05-07 |
2014-05-05 |
VP
Vente planifiée
|
WELCH DANIEL G
Chairman, CEO and President
Administrateur exécutif
|
28 913
-22.8%
33,39
965 370 USD
|
28 913
-22.8%
|
33,39
|
965 370 USD
|
|
|
2014-03-05 |
2014-03-04 |
VP
Vente planifiée
|
Leff Jonathan A
EVP of R&D
Dirigeant
|
20 000
-30.0%
31,51
630 286 USD
|
20 000
-30.0%
|
31,51
|
630 286 USD
|
|
|
2014-03-05 |
2014-03-04 |
V
Vente
|
Di Nepi Giacomo
EVP, Managing Director, Europe
Dirigeant
|
70 000
-72.6%
30,84
2 158 695 USD
|
70 000
-72.6%
|
30,84
|
2 158 695 USD
|
|
|
2014-02-27 |
2014-02-25 |
VP
Vente planifiée
|
HODGMAN JOHN
EVP-Finance & CFO
Dirigeant
|
73 130
-73.6%
35,69
2 610 010 USD
|
73 130
-73.6%
|
35,69
|
2 610 010 USD
|
|
|
2014-02-27 |
2014-02-25 |
VP
Vente planifiée
|
HODGMAN JOHN
EVP-Finance & CFO
Dirigeant
|
86 355
-46.5%
35,69
3 082 010 USD
|
86 355
-46.5%
|
35,69
|
3 082 010 USD
|
|
|
2014-02-27 |
2014-02-25 |
VP
Vente planifiée
|
WELCH DANIEL G
Chairman, CEO and President
Administrateur exécutif
|
41 087
-23.0%
32,63
1 340 767 USD
|
41 087
-23.0%
|
32,63
|
1 340 767 USD
|
|
|
2013-10-03 |
2013-10-01 |
VP
Vente planifiée
|
WELCH DANIEL G
Chairman, CEO and President
Administrateur exécutif
|
70 000
-30.8%
15,43
1 080 016 USD
|
70 000
-30.8%
|
15,43
|
1 080 016 USD
|
|
|
2013-09-04 |
2013-08-30 |
V
Vente
|
KABAKOFF DAVID S
|
10 002
-24.7%
14,82
148 245 USD
|
10 002
-24.7%
|
14,82
|
148 245 USD
|
|
|
2013-08-28 |
2013-08-27 |
A
Achat
|
Russell Angus C.
Administrateur non-exécutif
|
4 950
+53.8%
14,37
71 130 USD
|
4 950
+53.8%
|
14,37
|
71 130 USD
|
|
|
2013-08-28 |
2013-08-26 |
A
Achat
|
Russell Angus C.
Administrateur non-exécutif
|
1 650
+21.8%
15,00
24 743 USD
|
1 650
+21.8%
|
15,00
|
24 743 USD
|
|
|
2011-07-27 |
2011-07-27 |
VP
Vente planifiée
|
Bradford Williamson Z III
SVP-Clinical Science
Dirigeant
|
1 800
-2.8%
35,16
63 286 USD
|
1 800
-2.8%
|
35,16
|
63 286 USD
|
|
|
2011-07-21 |
2011-07-20 |
VP
Vente planifiée
|
Porter Steven Bryant
Chief Medical Officer
Dirigeant
|
7 290
-14.1%
36,25
264 242 USD
|
7 290
-14.1%
|
36,25
|
264 242 USD
|
|
|
2011-07-21 |
2011-07-20 |
VP
Vente planifiée
|
ARMSTRONG MARIANNE
SVP Ch Reg & Drug Safety Off
Dirigeant
|
7 250
-14.0%
36,23
262 694 USD
|
7 250
-14.0%
|
36,23
|
262 694 USD
|
|
|
2011-07-14 |
2011-07-13 |
VP
Vente planifiée
|
Bradford Williamson Z III
SVP-Clinical Science
Dirigeant
|
6 000
-8.9%
35,97
215 848 USD
|
6 000
-8.9%
|
35,97
|
215 848 USD
|
|
|
2011-07-07 |
2011-07-06 |
VP
Vente planifiée
|
ARMSTRONG MARIANNE
SVP Ch Reg & Drug Safety Off
Dirigeant
|
7 250
-14.0%
35,84
259 838 USD
|
7 250
-14.0%
|
35,84
|
259 838 USD
|
|
|
2011-07-07 |
2011-07-06 |
VP
Vente planifiée
|
Porter Steven Bryant
Chief Medical Officer
Dirigeant
|
7 290
-14.1%
35,82
261 118 USD
|
7 290
-14.1%
|
35,82
|
261 118 USD
|
|
|
2011-06-30 |
2011-06-29 |
VP
Vente planifiée
|
Bradford Williamson Z III
SVP-Clinical Science
Dirigeant
|
6 000
-8.9%
35,47
212 836 USD
|
6 000
-8.9%
|
35,47
|
212 836 USD
|
|
|
2011-06-23 |
2011-06-22 |
VP
Vente planifiée
|
Porter Steven Bryant
Chief Medical Officer
Dirigeant
|
7 290
-14.1%
32,03
233 462 USD
|
7 290
-14.1%
|
32,03
|
233 462 USD
|
|
|
2011-06-23 |
2011-06-22 |
VP
Vente planifiée
|
ARMSTRONG MARIANNE
SVP Ch Reg & Drug Safety Off
Dirigeant
|
7 250
-14.0%
35,02
253 909 USD
|
7 250
-14.0%
|
35,02
|
253 909 USD
|
|
|
2011-06-23 |
2011-06-21 |
VP
Vente planifiée
|
Porter Steven Bryant
Chief Medical Officer
Dirigeant
|
7 290
-14.1%
35,00
255 150 USD
|
7 290
-14.1%
|
35,00
|
255 150 USD
|
|
|
2011-06-23 |
2011-06-21 |
VP
Vente planifiée
|
ARMSTRONG MARIANNE
SVP Ch Reg & Drug Safety Off
Dirigeant
|
7 250
-14.0%
35,00
253 750 USD
|
7 250
-14.0%
|
35,00
|
253 750 USD
|
|
|
2011-06-23 |
2011-06-21 |
VP
Vente planifiée
|
Bradford Williamson Z III
SVP-Clinical Science
Dirigeant
|
6 000
-8.9%
35,00
210 000 USD
|
6 000
-8.9%
|
35,00
|
210 000 USD
|
|
|
2011-06-22 |
2011-06-20 |
V
Vente
|
Seiwert Scott
SVP, Rsearch & Technical Dev.
Dirigeant
|
6 297
-14.0%
33,22
209 188 USD
|
6 297
-14.0%
|
33,22
|
209 188 USD
|
|
|
2011-06-22 |
2011-06-20 |
V
Vente
|
Seiwert Scott
SVP, Rsearch & Technical Dev.
Dirigeant
|
23 891
-34.6%
33,15
791 987 USD
|
23 891
-34.6%
|
33,15
|
791 987 USD
|
|
|
2011-06-22 |
2011-06-20 |
V
Vente
|
Porter Steven Bryant
Chief Medical Officer
Dirigeant
|
7 321
-14.1%
34,00
248 914 USD
|
7 321
-14.1%
|
34,00
|
248 914 USD
|
|
|
2011-06-22 |
2011-06-20 |
V
Vente
|
ARMSTRONG MARIANNE
SVP Ch Reg & Drug Safety Off
Dirigeant
|
7 321
-14.1%
34,00
248 914 USD
|
7 321
-14.1%
|
34,00
|
248 914 USD
|
|
|
2011-06-21 |
2011-06-17 |
V
Vente
|
Steele Robin Joan
SVP, GC, Secretary
Dirigeant
|
38 721
-71.4%
33,78
1 307 995 USD
|
38 721
-71.4%
|
33,78
|
1 307 995 USD
|
|
|
2011-06-15 |
2011-06-14 |
V
Vente
|
Cohen Alan Howard
SVP, Medical Affairs
Dirigeant
|
20 849
-50.6%
33,00
688 017 USD
|
20 849
-50.6%
|
33,00
|
688 017 USD
|
|
|
2011-06-15 |
2011-06-14 |
V
Vente
|
Simon Howard Allan
SVP-Human Resources
Dirigeant
|
21 213
-46.8%
33,00
700 029 USD
|
21 213
-46.8%
|
33,00
|
700 029 USD
|
|
|
2011-06-10 |
2011-06-08 |
V
Vente
|
Simon Howard Allan
SVP-Human Resources
Dirigeant
|
9 578
-23.7%
33,00
316 074 USD
|
9 578
-23.7%
|
33,00
|
316 074 USD
|
|
|
2011-06-10 |
2011-06-08 |
V
Vente
|
Simon Howard Allan
SVP-Human Resources
Dirigeant
|
21 176
-34.4%
32,64
691 123 USD
|
21 176
-34.4%
|
32,64
|
691 123 USD
|
|
|
2011-06-03 |
2011-06-02 |
V
Vente
|
KABAKOFF DAVID S
Administrateur non-exécutif
|
2 000
-3.8%
36,41
72 819 USD
|
2 000
-3.8%
|
36,41
|
72 819 USD
|
|
|
2011-06-02 |
2011-06-01 |
VP
Vente planifiée
|
Bradford Williamson Z III
SVP-Clinical Science
Dirigeant
|
6 000
-8.3%
36,79
220 724 USD
|
6 000
-8.3%
|
36,79
|
220 724 USD
|
|
|
2011-06-02 |
2011-06-01 |
V
Vente
|
Porter Steven Bryant
Chief Medical Officer
Dirigeant
|
3 226
-5.4%
37,01
119 379 USD
|
3 226
-5.4%
|
37,01
|
119 379 USD
|
|
|
2011-06-02 |
2011-06-01 |
V
Vente
|
ARMSTRONG MARIANNE
SVP Ch Reg & Drug Safety Off
Dirigeant
|
3 186
-5.4%
36,50
116 301 USD
|
3 186
-5.4%
|
36,50
|
116 301 USD
|
|
|
2011-06-01 |
2011-05-31 |
V
Vente
|
Cohen Alan Howard
SVP, Medical Affairs
Dirigeant
|
36 189
-57.3%
37,16
1 344 762 USD
|
36 189
-57.3%
|
37,16
|
1 344 762 USD
|
|
|
2011-05-20 |
2011-05-18 |
V
Vente
|
Simon Howard Allan
SVP-Human Resources
Dirigeant
|
109 656
-73.1%
38,78
4 252 602 USD
|
109 656
-73.1%
|
38,78
|
4 252 602 USD
|
|
|
2011-05-19 |
2011-05-18 |
VP
Vente planifiée
|
Bradford Williamson Z III
SVP-Clinical Science
Dirigeant
|
6 000
-8.3%
37,17
223 018 USD
|
6 000
-8.3%
|
37,17
|
223 018 USD
|
|
|
2011-05-19 |
2011-05-18 |
VP
Vente planifiée
|
Porter Steven Bryant
Chief Medical Officer
Dirigeant
|
1 811
-3.0%
37,05
67 095 USD
|
1 811
-3.0%
|
37,05
|
67 095 USD
|
|
|
2011-05-19 |
2011-05-18 |
VP
Vente planifiée
|
ARMSTRONG MARIANNE
SVP Ch Reg & Drug Safety Off
Dirigeant
|
1 822
-3.0%
37,22
67 822 USD
|
1 822
-3.0%
|
37,22
|
67 822 USD
|
|
|
2011-05-18 |
2011-05-18 |
VP
Vente planifiée
|
WELCH DANIEL G
Chairman, CEO and President
Administrateur exécutif
|
20 750
-7.4%
37,22
772 323 USD
|
20 750
-7.4%
|
37,22
|
772 323 USD
|
|
|
2011-05-18 |
2011-05-17 |
V
Vente
|
Di Nepi Giacomo
SVP, Managing Director, Europe
Dirigeant
|
39 939
-61.9%
37,75
1 507 817 USD
|
39 939
-61.9%
|
37,75
|
1 507 817 USD
|
|
|
2011-05-18 |
2011-05-16 |
VP
Vente planifiée
|
WELCH DANIEL G
Chairman, CEO and President
Administrateur exécutif
|
3 505
-1.2%
38,22
133 961 USD
|
3 505
-1.2%
|
38,22
|
133 961 USD
|
|
|
2011-05-18 |
2011-05-16 |
V
Vente
|
Bradford Williamson Z III
SVP-Clinical Science
Dirigeant
|
958
-1.4%
37,78
36 193 USD
|
958
-1.4%
|
37,78
|
36 193 USD
|
|
|
2011-05-16 |
2011-05-13 |
V
Vente
|
Bradford Williamson Z III
SVP-Clinical Science
Dirigeant
|
1 918
-2.8%
39,85
76 425 USD
|
1 918
-2.8%
|
39,85
|
76 425 USD
|
|
|
2011-05-16 |
2011-05-12 |
VP
Vente planifiée
|
Steele Robin Joan
SVP, GC, Secretary
Dirigeant
|
187 887
-75.3%
38,59
7 250 315 USD
|
187 887
-75.3%
|
38,59
|
7 250 315 USD
|
|
|
2011-05-16 |
2011-05-12 |
V
Vente
|
HODGMAN JOHN
SVP-Finance & CFO
Dirigeant
|
143 227
-86.7%
40,00
5 729 080 USD
|
143 227
-86.7%
|
40,00
|
5 729 080 USD
|
|
|
2011-05-16 |
2011-05-12 |
V
Vente
|
ARMSTRONG MARIANNE
SVP Ch Reg & Drug Safety Off
Dirigeant
|
131 332
-69.2%
40,14
5 271 732 USD
|
131 332
-69.2%
|
40,14
|
5 271 732 USD
|
|
|
2011-05-16 |
2011-05-12 |
V
Vente
|
Bradford Williamson Z III
SVP-Clinical Science
Dirigeant
|
115 842
-63.2%
38,84
4 499 118 USD
|
115 842
-63.2%
|
38,84
|
4 499 118 USD
|
|
|
2011-05-16 |
2011-05-12 |
V
Vente
|
Porter Steven Bryant
Chief Medical Officer
Dirigeant
|
88 311
-60.1%
38,89
3 434 256 USD
|
88 311
-60.1%
|
38,89
|
3 434 256 USD
|
|
|
2011-05-16 |
2011-05-12 |
V
Vente
|
Seiwert Scott
SVP, Rsearch & Technical Dev.
Dirigeant
|
71 443
-60.3%
39,13
2 795 229 USD
|
71 443
-60.3%
|
39,13
|
2 795 229 USD
|
|
|
2011-05-05 |
2011-05-04 |
VP
Vente planifiée
|
Porter Steven Bryant
Chief Medical Officer
Dirigeant
|
5 500
-8.7%
44,03
242 164 USD
|
5 500
-8.7%
|
44,03
|
242 164 USD
|
|
|
2011-05-05 |
2011-05-04 |
VP
Vente planifiée
|
Bradford Williamson Z III
SVP-Clinical Science
Dirigeant
|
6 000
-8.3%
44,09
264 565 USD
|
6 000
-8.3%
|
44,09
|
264 565 USD
|
|
|
2011-05-05 |
2011-05-04 |
VP
Vente planifiée
|
ARMSTRONG MARIANNE
SVP Ch Reg & Drug Safety Off
Dirigeant
|
5 651
-8.9%
44,03
248 816 USD
|
5 651
-8.9%
|
44,03
|
248 816 USD
|
|
|
2011-04-21 |
2011-04-20 |
VP
Vente planifiée
|
Bradford Williamson Z III
SVP-Clinical Science
Dirigeant
|
6 000
-8.3%
46,43
278 606 USD
|
6 000
-8.3%
|
46,43
|
278 606 USD
|
|
